Encysive TBC3711 On Clinical Hold
This article was originally published in The Pink Sheet Daily
Executive Summary
Encysive's next-generation selective endothelin receptor antagonist TBC3711 is subject to a clinical hold following an unexpected result in pre-clinical work
You may also be interested in...
Encysive Hits Another Snag With Thelin
FDA requests the company reformat information included in its response to a second “approvable” letter.
Encysive Hits Another Snag With Thelin
FDA requests the company reformat information included in its response to a second “approvable” letter.
Encysive Avoids Additional Trials For Thelin NDA
The firm has submitted a complete response to a recent FDA “approvable” letter using existing data for the pulmonary arterial hypertension drug.